ArticleCrohn's & colitis 3602024

Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study.

Thea H Wiken et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.